Share

There are a number of FDA-approved drugs that have shown efficacy in preclinical studies for addressing the aging processes. Drugs such as rapamycin, dasatinib, and quercetin among others have all showed promise in animal studies.

Non-profit Betterhumans, known for its educational and news-related work in the transhumanist community, has announced that it will be running a series of pilot studies on interventions against aging using FDA-approved drugs and therapies, and it intends to make all results publicly available in the interest of transparency.

Human trials with approved drugs that show potential for targeting an aging process

The organization plans to begin with a trial of dasatinib and quercetin, a combination that has enjoyed success in mice in a number of studies recently [1-2]. With these compounds already approved for human use, and the removal of senescent cells being the low-hanging fruit in aging research, it makes sense for Betterhumans to begin here.

The small-scale trials of senolytic therapies aim to remove toxic senescent cells from the body, as they have already proven to do so in mice in a bid to address age-related diseases. The removal of senescent cells has been a hot topic in the last year or so, with various groups entering human clinical trials.

However, the arrival of these new drugs could be some years away, as the clinical trial process is a long one; Betterhumans is looking for solutions people can use now while they wait for better things to arrive, so it is proposing to test drugs that are already approved. 

We intend to pursue many small-scale human pilot studies to test the safety and efficacy of various FDA-approved drugs and therapies thought to have anti-aging effects. We will publish all results so that other researchers, physicians, and patients can have information which may aid their efforts.

One question they seek to answer in this Phase 0 pilot study is whether the senolytic compounds dasatinib and quercetin will significantly eliminate senescent cells contained in the muscle and fat tissue of elderly individuals who have metabolic syndrome and/or osteoarthritis, and the study will test if they will reduce levels of systemic inflammation and insulin resistance, improve the patients’ immunological responses, and reverse the progression of osteoarthritis.

There is already a wealth of animal data for senolytics, and groups like Betterhumans are keen to make use of existing drugs to potentially address aging processes. This lets people benefit from them in the immediate future while more refined therapies are developed.

We do, however, stress that such testing is not without risks and should only be conducted in the context of properly designed studies, such as those proposed here and by qualified professionals. In short, don’t try this at home, folks.

Conclusion

As its website states, Betterhumans is investigating a number of age-related diseases and the effect of these two compounds on them. In mouse studies, these compounds eliminated senescent cells, improved mouse health and, in some cases, even increased lifespan.

Will we see a translation of these positive results to humans? These pilot studies aim to find out, and we would like to see more properly organized, transparent studies being conducted. We will be doing an interview with James Clement from Betterhumans in the near future and learning more about this initiative, so stay tuned.

Literature

[1] Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., … & O’hara, S. P. (2015). The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs. Aging cell, 14(4), 644-658.

[2] Roos, C. M., Zhang, B., Palmer, A. K., Ogrodnik, M. B., Pirtskhalava, T., Thalji, N. M., … & Zhu, Y. (2016). Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice. Aging Cell, 15(5), 973-977.

CategoryNews
About the author

Steve Hill

Steve serves on the LEAF Board of Directors and is the Editor in Chief, coordinating the daily news articles and social media content of the organization. He is an active journalist in the aging research and biotechnology field and has to date written over 500 articles on the topic as well as attending various medical industry conferences. In 2019 he was listed in the top 100 journalists covering biomedicine and longevity research in the industry report – Top-100 Journalists covering advanced biomedicine and longevity created by the Aging Analytics Agency. His work has been featured in H+ magazine, Psychology Today, Singularity Weblog, Standpoint Magazine, and, Keep me Prime, and New Economy Magazine. Steve has a background in project management and administration which has helped him to build a united team for effective fundraising and content creation, while his additional knowledge of biology and statistical data analysis allows him to carefully assess and coordinate the scientific groups involved in the project. In 2015 he led the Major Mouse Testing Program (MMTP) for the International Longevity Alliance and in 2016 helped the team of the SENS Research Foundation to reach their goal for the OncoSENS campaign for cancer research.
Write a comment:

*

Your email address will not be published.

© 2018 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

       Powered by MMD